$BTI

BAT Lifts Annual Profit Growth Target As Velo Drives US Momentum

British American Tobacco (BAT) raised its full-year adjusted EPS growth outlook to the middle of its 5% to 8% medium-term range, up from earlier guidance at the low end, citing strong US momentum and demand for its Velo nicotine pouches, offsetting weaker Asia. It kept revenue and adjusted operating profit growth at the low end of 3% to 5% and 4% to 6%. Six-month adjusted EPS was 164p, up 7.9% vs a 158.5p consensus.

Original reporting
Published Jul 30, 2026, 9:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 11:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BAT Lifts Annual Profit Growth Target As Velo Drives US Momentum — source image
Decision brief

The 30-second read

$BTIBullishMed
01

Why it matters

The company increased its full-year adjusted EPS growth expectation toward the middle of its medium-term range, attributing improvement to Velo demand and US momentum while acknowledging Asia weakness and an AI-driven restructuring.

02

Market read

A guidance step-up tied to modern oral momentum can drive re-rating, but the stock’s early weakness signals investors are still weighing restructuring and regional demand risks.

03

What to watch

The article does not quantify restructuring cost impact or the sustainability of Velo growth; traders may need to watch margin and volume share trends beyond the stated category growth.

Relevance 7/10Novelty 7/10Timing: pre-market today, with early trading shares down as guidance was adjusted

Background

BAT is transitioning profits away from traditional cigarettes via investments in smoking alternatives, including nicotine pouches (Velo) and modern oral categories.

Company-level read

Ticker impact

$BTIBullishMedium confidence
Context

BAT raised its full-year adjusted EPS growth outlook toward the mid of its 5% to 8% range, citing Velo strength and US momentum.

Expected impact

Near-term bias higher as investors re-rate the earnings trajectory; follow-through depends on whether Velo and US trends persist despite Asia weakness.

Evidence & confidence

The article is a fresh guidance update with specific directional change and supporting operating drivers (Velo, US), plus explicit headwinds (Asia decline, restructuring, AI-driven job cuts).

Market effects

Reinforces the shift from combustible cigarettes to modern oral and vapes, highlighting nicotine pouch momentum as a driver of earnings expectations.

US outperformance is explicitly offsetting Asia demand declines, suggesting regional divergence in tobacco demand trends.

Could influence how investors model peers’ modern oral growth and restructuring execution risk across major markets.

Counterpoint

The guidance lift may be more about mix and timing than durable demand, especially with Asia still sharply weaker and restructuring excluding the US.

Key entities

  • British American Tobacco

    Raised full-year adjusted EPS growth outlook, citing Velo nicotine pouch demand and strong US performance, while noting Asia decline and restructuring.

  • Velo

    Nicotine pouch brand whose surging demand is cited as a key driver of US momentum and earnings outlook.

  • Accenture

    Named as a beneficiary of shifted roles to third parties in BAT’s restructuring plan.

  • US FDA

    Cited as enabling sales of some unlicensed vapes, potentially expanding the US market for BAT’s alternatives.

Related articles

$PMMed

Philip Morris (PM) Bets $1.2B on ZYN as BAT (BTI) Steps Up Its Pouch Push

Philip Morris International (PM) opened a $1.2B, 780,000 sq ft Aurora, Colorado campus to produce ZYN nicotine pouches, after about 19 months. The FDA authorized 20 ZYN products as modified risk tobacco products on June 30. Reuters also cited PM beating Q2 estimates. The article notes Aurora cost rose from $600M and highlights BAT (BTI) growth and planned Velo Max rollout.

$BTIMedAI 8/10

BRITISH AMERICAN TOBACCO PLC – British American Tobacco Announces Pricing of $1,500,000,000 Notes Offerings - Sens

British American Tobacco (BAT) said its wholly owned subsidiary B.A.T. Capital Corporation priced a $1.5 billion notes offering. It includes $750 million 5.300% notes due 2033 and $750 million 5.550% notes due 2036, guaranteed by BAT and other entities including Reynolds American Inc. Expected to close 5 Aug 2026. Net proceeds for general corporate purposes, including potential debt repayment.

$BTIMedAI 8/10

BTI Q2 2026 Earnings Call Transcript

British American Tobacco (BTI) Q2 2026 earnings call reported 2.9% group revenue growth at constant currency and a 7.9% rise in adjusted diluted EPS. New Category revenue grew 18%, with Modern Oral up 66%. Smokeless was 19.8% of revenue. Full-year EPS guidance was upgraded to the mid of 5% to 8%, with GBP 1.3bn buyback for 2026 and Fit2Win savings of GBP 700m by 2028.

$BTIMed

BTI Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Tadeu Marroco Interim Chief Financial Officer - Javed Iqbal Group Head of Investor Relations - Victoria Buxton TAKEAWAYS Group Revenue -- 2.9% growth at constant currency, reflecting multi-category performance in the U.S. and an acceleration in New Category growth. Adjusted Diluted EPS -- 7.9% increase, supported by lower net finance costs following debt repayment and 4.4% growth from earning kickers.

$BTIMed

BAT must face class-action litigation over cigarette labels, US appeals court rules By Reuters

A divided U.S. appeals court ruled British American Tobacco’s Natural American Spirit cigarette labeling claims can proceed as class actions. The 10th Circuit upheld certification of menthol-related claims and set aside denial of “safer cigarette” claims, allowing consumers in 12 states to seek damages. Reuters reports the case was returned to a district judge for further proceedings.